Delcath Systems, Inc. (NASDAQ:DCTH) Receives Average Recommendation of “Moderate Buy” from Analysts

Posted by on Sep 18th, 2026

Delcath Systems, Inc. (NASDAQ:DCTH – Get Free Report) has been given an average recommendation of “Moderate Buy” by the seven ratings firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $23.1667.

Several research analysts have recently weighed in on DCTH shares. BTIG Research lifted their price objective on Delcath Systems from $17.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Wall Street Zen raised Delcath Systems from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Weiss Ratings upgraded Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, September 4th. HC Wainwright reissued a “buy” rating and issued a $32.00 price target (up from $30.00) on shares of Delcath Systems in a research note on Friday, August 7th. Finally, Zacks Research raised shares of Delcath Systems from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 10th.

Get Our Latest Stock Report on DCTH

Hedge Funds Weigh In On Delcath Systems

Several institutional investors have recently made changes to their positions in the stock. Private Wealth Advisors LLC grew its stake in shares of Delcath Systems by 85.9% in the 4th quarter. Private Wealth Advisors LLC now owns 290,481 shares of the company’s stock valued at $2,934,000 after buying an additional 134,198 shares during the period. Royce & Associates LP bought a new position in Delcath Systems in the fourth quarter worth approximately $1,566,000. Bank of New York Mellon Corp bought a new stake in shares of Delcath Systems during the second quarter valued at approximately $1,362,000. Bank of America Corp DE increased its holdings in shares of Delcath Systems by 54.0% during the first quarter. Bank of America Corp DE now owns 57,729 shares of the company’s stock valued at $536,000 after acquiring an additional 20,249 shares in the last quarter. Finally, Sei Investments Co. raised its position in shares of Delcath Systems by 100.0% during the first quarter. Sei Investments Co. now owns 44,058 shares of the company’s stock worth $409,000 after purchasing an additional 22,029 shares during the period. Institutional investors and hedge funds own 61.12% of the company’s stock.

Delcath Systems Stock Up 0.2%

DCTH opened at $16.25 on Friday. Delcath Systems has a twelve month low of $8.12 and a twelve month high of $17.42. The company has a fifty day moving average of $14.99 and a 200-day moving average of $12.26. The stock has a market cap of $563.86 million, a PE ratio of 1,626.63 and a beta of 0.57.

Delcath Systems (NASDAQ:DCTH – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.16. The business had revenue of $29.13 million for the quarter, compared to analyst estimates of $26.25 million. Delcath Systems had a net margin of 0.56% and a return on equity of 0.46%. Sell-side analysts anticipate that Delcath Systems will post -0.17 EPS for the current fiscal year.

Delcath Systems Company Profile

(Get Free Report)

Delcath Systems, Inc (NASDAQ:DCTH) is an oncology company focused on developing and commercializing liver-directed therapies for patients with primary and metastatic cancers of the liver. Its technology is designed to deliver high concentrations of chemotherapy to the liver while limiting systemic exposure.

The company’s primary product is the HEPZATO KIT, a combination of melphalan hydrochloride and the Hepatic Delivery System. The treatment is used to perform percutaneous hepatic perfusion, a procedure in which the liver is temporarily isolated so chemotherapy can be administered directly to it and then filtered before the blood returns to the patient’s circulation.

Featured Articles

Analyst Recommendations for Delcath Systems (NASDAQ:DCTH)

Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.